PhaseV is a technology company harnessing the power of ML to innovate the drug development process, powering more efficient, advanced, and successful clinical trials.
Their proprietary platform for adaptive trial design and execution promotes the adoption of advanced dynamic clinical trials, enabling sponsors to significantly improve efficiency and effectiveness while maximizing patient benefits.
In addition, their novel causal-ML pipeline enables the detection of hidden signals in clinical trial data, identifying heterogeneous treatment effects at a much finer level than otherwise possible, and providing meaningful and actionable insights for the design of the next study, to increase trial success rate.
PhaseV is headquartered in Boston and brings together a unique combination of machine learning, software engineering, and data science experts with leaders in advanced and Bayesian statistics and clinical and pharma veterans, enabling to harness the latest technological advancements and tailor them to the unique requirements of the clinical development process.
Go To Site
